Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia

Published:2012-06 Issue:3 Volume:12 Page:207-212
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cervera Eduardo,Candelaria Myrna,López-Navarro Omar,Labardini Juan,Gonzalez-Fierro Aurora,Taja-Chayeb Lucia,Cortes Jorge,Gordillo-Bastidas Daniela,Dueñas-González Alfonso

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference46 articles.

1. The molecular biology of chronic myeloid leukemia;Deininger;Blood,2000

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

4. 15-deoxy-Δ12,14-PGJ2 enhances platelet production from megakaryocytes

5. Survival benefit with imatinib mesylate versus interferon-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy;Discover Oncology;2024-08-11

2. Patenting trends in the pharmaceutical field of Mexican universities;Pharmaceutical Patent Analyst;2023-01

3. Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing;Frontiers in Pharmacology;2022-04-01

4. Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine;Frontiers in Oncology;2022-02-02

5. Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer;Biomedicines;2021-08-07